Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
Metrics to compare | TYP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTYPPeersSector | |
---|---|---|---|---|
P/E Ratio | - | −6.2x | −0.5x | |
PEG Ratio | - | −0.01 | 0.00 | |
Price/Book | 11.2x | 1.9x | 2.6x | |
Price / LTM Sales | - | 10.5x | 3.2x | |
Upside (Analyst Target) | - | 73.3% | 44.3% | |
Fair Value Upside | Unlock | 13.9% | 6.6% | Unlock |